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Abstract: Endocrine therapy is a key treatment strategy to control or eradicate  
hormone-responsive breast cancer. However, resistance to endocrine therapy leads to 
breast cancer relapse. The recent extension of adjuvant tamoxifen treatment up to 10 years 
actualizes the need for identifying biological markers that may be used to monitor 
predictors of treatment response. MicroRNAs are promising biomarkers that may fill the 
gap between preclinical knowledge and clinical observations regarding endocrine resistance. 
MicroRNAs regulate gene expression by posttranscriptional repression or degradation of 
mRNA, most often leading to gene silencing. MicroRNAs have been identified directly in 
the primary tumor, but also in the circulation of breast cancer patients. The few available 
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studies investigating microRNA in patients suggest that seven microRNAs (miR-10a,  
miR-26, miR-30c, miR-126a, miR-210, miR-342 and miR-519a) play a role in tamoxifen 
resistance. Ingenuity Pathway Analysis (IPA) reveals that these seven microRNAs interact 
more readily with estrogen receptor (ER)-independent pathways than ER-related signaling 
pathways. Some of these pathways are targetable (e.g., PIK3CA), suggesting that 
microRNAs as biomarkers of endocrine resistance may have clinical value. Validation of 
the role of these candidate microRNAs in large prospective studies is warranted. 
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1. Introduction 
Breast cancer is a heterogenic disease that demands an individualized treatment plan, incorporating 
both patient and tumor information. The development of breast cancer is a highly complicated 
biological process in which the alteration of women’s physiology and the hormonal status plays a 
significant role [1]. The biological profile of breast cancer differs between the very young (<45 years) 
and elderly patients (>70 years). Tumors of younger patients are more often Estrogen Receptor alpha 
(ER) negative (30% are ER−) with higher average proliferation (Mitotic Activity Index (MAI) = 12.8), 
while elderly patients more often present with ER positive tumors (90% are ER+) and a much lower 
average proliferation (MAI = 8.7) [2]. Currently, biomarkers such as ER, Progesterone Receptor  
(PgR) and the Human Epidermal growth factor-like Receptor 2 (HER2) expression level, as well as 
proliferation status as measured by Ki-67, roughly distinguish patients according to breast cancer 
subtypes and help inform treatment choice [3,4]. These biomarkers represent important biological 
processes in the development and progression of breast cancer. In addition to these biological factors, 
clinical characteristics including the extent of cancer spread, tumor size, lymph node involvement,  
and evidence of any metastases (TNM), are used to determine the most effective treatment course.  
For most breast cancer patients, surgical removal of the tumor is primary treatment. In addition, 
depending on the specific characteristics of the individual tumor, adjuvant therapy comprising 
systemic treatment with chemotherapy, endocrine therapy, anti-HER2 treatment and/or zoledronic 
acid, and postoperative radiation therapy are recommended to reduce the risk of relapse [5]. 
Despite the effectiveness of surgery and extensive adjuvant treatments in breast cancer, challenges 
concerning over- and under-treatment and recurrence prediction persist. Over-treatment can induce 
temporary or chronic side effects, significantly lowering quality of life. On the other hand, under-treatment 
can lead to disease recurrence and metastasis, almost always with life-threatening consequences. 
Two-thirds of breast cancer patients have ER+ tumors and are candidates for endocrine therapy [6,7]. 
Tamoxifen is recommended for premenopausal women, in whom aromatase inhibitors (AIs) are 
contraindicated [8], whereas AIs are the treatment of choice for postmenopausal women. Still, 
tamoxifen is an alternative or sequential treatment for postmenopausal patients, depending on their risk 
of tamoxifen side effects [9,10]. Endocrine therapy reduces the five-year recurrence risk by about  
one-half [6]. However, patients with identical prognostic factors at diagnosis can vary substantially in 
their clinical course and treatment response. Endocrine therapy resistance can either exist from the start 
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of diagnosis (de novo/intrinsic resistance) or develops during the course of treatment (acquired 
resistance) [11]. Unfortunately, resistance to therapy as well as over- and under-treatment, are difficult 
to foresee with the current biomarkers. Thus, acquired resistance is hard to predict before a local or 
systemic relapse has occurred and becomes clinically overt. Therefore, improved prognostic and 
predictive biomarkers (measured in the primary tumor), as well as biomarkers for monitoring drug 
response (measured in blood) are urgently needed. 
While many new biomarkers have been described over the last decades very few have made it from 
the laboratory into the clinic. Pultz et al. recently reviewed several biomarkers from relevant literature 
and sorted them according to their potential clinical relevance. They suggested that 15 of these markers 
should be validated in the clinic; amongst which microRNA was mentioned [12]. MicroRNAs are a 
short form of non-coding single-stranded RNA about 22 nucleotides in length. MicroRNAs regulate 
gene expression by posttranscriptional repression or degradation of mRNA, most often leading to gene 
silencing [13]. 
Although recently discovered, a great body of evidence is accumulating implying that miRNAs might 
provide both predictive and prognostic potential as biomarkers. In this review, we discuss the potential 
clinical utility of microRNAs as determinants of tamoxifen resistance in breast cancer patients, and how 
and where they interact with biological pathways in order to mediate such tamoxifen resistance. 
1.1. Estradiol and the Estrogen Receptor 
As illustrated in Figure 1, the biological activities of estrogens are mediated by ERs, which upon 
activation by cognate ligands form homodimers, or heterodimers with other ER-ligand complexes [14,15], 
and activate transcription of specific genes containing the estrogen response element (ERE) [16,17]. 
1.2. Endocrine Treatment Regimens 
Endocrine treatment regimens for breast cancer patients comprise a dual strategy by either blocking 
the estrogen action at the ER-level (tamoxifen), or by inhibition of the in vivo estrogen synthesis in the 
whole body. In postmenopausal patients the latter is achieved by AIs alone, while pre-menopausal 
women need ovarian function suppression (OFS) and AIs in concert. The current treatment regimens 
for pre-, peri- and postmenopausal ER+ breast cancer women in Norway are illustrated in Figure 2. 
These national guidelines are based on international recommendations [3], and are similar to the 
guidelines of the National Comprehensive Cancer Network [5]. Note that endocrine treatment has been 
extended to 10 years of treatment as a result of recent publications [7,18]. 
Tamoxifen is a selective ER modulator (SERM) and the most frequently used anti-estrogen adjuvant 
treatment for ER+ pre-menopausal women. Tamoxifen is also a standard endocrine therapy for treatment 
of postmenopausal women with breast cancer, although AIs are more frequently used (see Figure 2 
above). Depending upon the tissue, tamoxifen may function as an agonist or antagonist, recruiting 
either coactivators or corepressors to the ER transcription complex [19]. Tamoxifen exhibits antagonistic 
effects in breast tissue, thus has preventive effects on breast cancer development [20] and cytotoxic 
effects on breast cancer cells [21]. Tamoxifen also exerts agonistic effects in the uterus, increasing the 
risk of endometrial hyperplasia and malignancy [22]. 
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Figure 1. Simplified possible molecular signaling pathways (1 to 6) of estrogen (E) and 
estrogen receptors (ER). (1) Classical and direct pathway: ligand activation is followed by 
binding to the estrogen response element (ERE), including coactivators (CoA) and histone 
acetyl transferases (HATs) before gene regulation is modified; (2) tethered pathway: ligand 
dependent pathway which includes protein-protein interaction with other transcription 
factors, e.g., activator protein 1 (Ap1) and specificity protein 1 (Sp1), after ligand activation, 
thereby regulating genes by indirect DNA binding following serum response element 
(SRE) activation of transcription; (3) non-genomic ligand dependent reaction: the receptor 
(e.g., classical ER, ER isoform or other receptors) is activated by a ligand, which may be 
associated with the membrane. This is then followed by signaling cascades initiated by 
second messengers (SM), initiating a rapid physiological response, which does not involve 
gene regulation; (4) ligand-dependent reaction: ER is methylated by ligand induction and 
ER–phosphoinositide 3-kinase (PI3K)–steroid receptor coactivator (SRC)-focal adhesion 
kinase (FAK) forms a complex that further activates the serine/threonine–protein kinase Akt, 
which then activates transcription without ER binding to DNA; (5) ligand independent 
reaction: ER–SRC–proline-, glutamic acid and leucine-rich protein 1 (PELP1) forms a 
complex which then activates transcription, also without ER binding to DNA; (6) another 
ligand independent reaction activates through other signaling pathways, like growth factor 
signaling by downstream events of receptor tyrosine kinase (RTKs), such as epidermal 
growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2) and the  
insulin-like growth factor receptor (IGFR) [11,23]. 
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Figure 2. Overview of the adjuvant endocrine treatment guidelines for ER+ breast cancer 
patients according to the Norwegian Breast Cancer Group (NBCG) 2015 [24], and based 
on international recommendations (St. Gallen, 2013). There are two options for premenopausal 
patients (1 and 2 on the left side) and five options for postmenopausal patients (1–5 on the 
right side) comprising aromatase inhibitor (AI), tamoxifen and ovarian function suppression 
(OFS) alone or in combination. Total duration of endocrine treatment for a premenopausal 
patient that becomes postmenopausal after two or five years on tamoxifen (example) is 
illustrated in brackets. The choice between alternatives 1–5 is made individually based 
upon tumor biology, side effects and preferences among clinicians and patients.  
Peri: perimenopausal; TAM: tamoxifen; Yrs: years; Dotted line: years on tamoxifen;  
Solid line: years on AI. 
The tamoxifen metabolic pathway is complex. In general, tamoxifen is oxidized in the liver by 
phase I metabolism involving various enzymes encoded by polymorphic genes including cytochrome 
P450 2D6 (CYP2D6) into two active metabolites: 4-hydroxy-N-desmethyl tamoxifen (endoxifen) and  
4-hydroxytamoxifen (4-OHT). Endoxifen and 4-OHT then undergo phase II conjugation reactions and 
further find their way into the cancer cells. In breast cancer cells, 4-OHT acts as an antagonist 
preventing estrogen from binding to the ER, thus preventing proliferation and cell growth [25,26]. 
Levels of estrogen have been correlated with tamoxifen metabolite concentration in serum [27,28]. 
Due to polymorphic metabolic enzymes in the tamoxifen pathway, there are inter-individual differences 
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in the concentration of the active metabolites in serum and therefore a potential for variation in drug 
effectiveness [29]. The serum concentration of tamoxifen and its metabolites increases with age, which 
could explain part of the inter-patient variation of active metabolite concentration in serum [30]. 
In postmenopausal patients, peripheral conversion of androgens into estrogens takes place in 
various tissues [31]. Third generation AIs cause more than 98% inhibition of this extra-ovarian 
aromatase activity and create extremely low serum and tissue levels of estrogens [32,33]. The systemic 
hypo-estrogenic state produced by AIs may explain their superiority to tamoxifen when administered 
upfront adjuvantly in postmenopausal patients [34,35]. However, this beneficial difference in survival 
disappears after two years of AI treatment [35], and therefore tamoxifen treatment for at least three 
years might also follow in postmenopausal patients [24] (Figure 2). 
1.3. Resistance to Tamoxifen 
In approximately 30% of ER+ breast cancer patients, endocrine treatment fails due to tamoxifen 
resistance [36]. As illustrated in Figure 3, mechanisms of tamoxifen resistance may involve changes in the 
activity of enzymes that metabolize tamoxifen, loss or modification of ER expression, alterations in the 
balance of co-regulatory proteins, altered expression of specific microRNAs, or the activation of 
alternative signal transduction pathways that can further promote tumor growth [37,38]. Regardless,  
it is likely that the pathways involved in de novo versus acquired resistance are different [39]. Therefore, 
monitoring the development of resistance to tamoxifen and the exploration of new therapeutic targets 
is pivotal. 
1.4. MicroRNAs 
MicroRNAs are defined as short non-protein-coding RNA molecules, of which the mature form is 
about 22 nucleotides in length. Each microRNA is complementary or partially complementary to one 
or more mRNA molecules, and its main function is to post-transcriptionally down-regulate gene 
expression by either binding directly to its mRNA target, or by cleaving target mRNA by binding to its 
3′-UTR region. According to the microRNA database miRBase v.21, more than 2603 human microRNAs 
have been identified so far [40]. A single microRNA can potentially target up to 200 mRNAs; and the 
same mRNA molecule may also be targeted by different microRNAs [41,42], underlining the wide 
range and complexity of their functions. MicroRNAs have been shown to play a pivotal role in 
numerous biological processes, cellular pathways and networks. Many major cellular functions such as 
development, differentiation, growth, metabolism, survival, motility and proliferation are, in part, regulated 
by microRNAs. Since the link between cancer and microRNAs was first demonstrated in 2002 [43], 
microRNAs have also been shown to be involved in multiple cancer types, and microRNA-encoding 
genes are often located at genomic regions known to be associated with cancer [44]. More specifically, 
microRNAs are often involved in mechanisms underlying tumorigenesis and tumor progression, where 
they act as either tumor suppressor microRNAs or as tumor-promoting microRNAs [45]. 
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Figure 3. The tamoxifen pathway and possible mechanisms of endocrine resistance in 
breast cancer cells. Prior to entering the breast cancer cell, tamoxifen (T) is metabolized in 
the liver into the two active metabolites, endoxifen and 4-hydroxytamoxifen (4-OHT). 
When these metabolites enter the cell (blue background) they can bind to estrogen receptors 
(ERs), thereby blocking the binding of estrogen. ERs bound to tamoxifen then dimerize, 
enter the nucleus and bind to estrogen response element (ERE). However, the necessary 
coactivators will not be recruited by the ER–tamoxifen complex. Only corepressors are 
recruited, therefore gene transcription is not activated. In tamoxifen resistance, this blocking 
is compromised due to several possible mechanisms: e.g., changes in activity of the 
metabolizing enzymes of tamoxifen, loss or modification of ER expression, alternative 
signaling pathways for proliferation and growth, and alterations in the balance of  
co-regulatory proteins and altered expression of microRNAs [37,39]. Black arrow: normal 
estrogen pathway. Blue arrow: tamoxifen pathway. Crossed arrow: disrupted pathway. 
2. Methods 
2.1. Literature Search 
To find relevant original articles for tamoxifen related microRNA, we performed a search in PubMed 
on the first of July 2015 using the words “microRNA” and “tamoxifen” (89 articles), filtering for 
human species (53 articles). Further selection, excluding review articles and focusing on studies that 
included patient material only, resulted in six studies [46–51] (see Table 1). 
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Table 1. Candidate microRNAs involved in tamoxifen response. 
MicroRNA Material and Patients Clinical Outcome Reference Predicted Targets or Pathways 
miR-342-5p 
FFPE of tamoxifen-treated 
primary tumor, n = 16 
Ten patients responded to tamoxifen and had non-recurrent 
disease: two-fold the level of miR-342 expression;  
Six patients developed recurrences and metastasis during 
tamoxifen treatment and had low levels of miR-342 
[46] 
Target genes: GEMIN4 and BMP7  
Predicted pathways: cell death,  
apoptosis of breast cancer cells,  
mitotic roles of polo-like kinase 
miR-30c-5p 
Primary tumors,  
tamoxifen-treated following 
advanced disease, n = 246 
Increasing levels of miR-30c was associated with clinical benefit 
of tamoxifen treatment, as measured by longer PFS 
[49] 
Target genes: PPARGC1B, Makorin-3, 
UBAC1, PTPDC1  
Predicted pathways: HER2,  
signal ransduction, and oncology pathway, 
RAC1 cell motility signaling pathway 
miR-210-3p  
Fresh-frozen tamoxifen-treated 
primary tumors, n = 89 
High level of miR-210 expression was associated with a higher 
risk of recurrence than a lower level of miR-210 
[50] 
Target genes:ACVR1B, CBFA2T1  
Predicted pathways: cell cycle, cell adhesion 
and immune response 
miR-26a 
Frozen tamoxifen-treated 
tumors of metastatic patients, 
n = 235 
Higher levels of miR-26a were significantly associated with clinical 
benefit (i.e., complete or partial response, or stable disease), and 
with favorable TTP (i.e., first detection of disease progression) 
[51] 
Target genes: CDC2, CCNE1  
Predicted pathways: cell cycle  
regulation pathway 
miR-126-5p and  
miR-10a-5p 
FFPE from postmenopausal 
tamoxifen-treated patients, 
Validation set:  
n = 34 with recurrence;  
n = 47 without recurrence 
Low expression of miR-10a and miR-126 correlated significantly 
with reduced relapse-free time 
[47] 
Target genes: n/a  
Predicted pathways: n/a 
miR-519a-3p 
GEO datasets of breast cancer 
patients, Discovery set:  
n = 632, Validation set:  
n = 586 
High expression of miRNA-519a correlated significantly with 
poorer disease-free survival in ER+ breast cancer patients 
[48] 
Target genes: PTEN, RB1, CDKN1A/p21  
Predicted pathways: PI3K/Akt pathway 
FFPE: Formalin-fixed and paraffin-embedded; GEO: Gene Expression Omnibus; PFS: progression-free survival; TTP: time to progression. 
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2.2. Ingenuity Pathway Analysis 
To investigate the biological interactions of the seven tamoxifen-related microRNAs from our 
literature search with other molecules, we used in silico analysis to find predicted targets and identify 
their corresponding networks. The predicted targets and networks were generated through the use of 
QIAGEN’s Ingenuity Pathway Analysis (IPA®, QIAGEN, Redwood City, CA, USA). This software 
collects information about molecule-to-molecule interactions, biological networks and canonical 
pathways in the Ingenuity Knowledge database. This information is also reviewed by experts to ensure 
good quality information. Additionally, the software calculates a p value (right-tailed Fisher’s exact 
test) to determine the probability that the input genes are connected to a verified network or pathway 
by chance alone. 
First, we used IPA to find the experimentally observed and highly predicted targets for each of the 
seven microRNAs, to be used further in an IPA core analysis (see Table 2). Then, for each of the 
resulting target lists, we used IPA to perform a core analysis considering only direct relationships 
between molecules, in humans, resulting in biological networks (see Figures 4–6). 
Table 2. Number of experimentally observed and highly predicted gene targets for the 
candidate microRNAs listed in Table 1. 
MicroRNA No. of Target Genes 
miR-342-5p 337 
miR-30c-5p 1420 
miR-210-3p 78 
miR-26a 892 
miR-126a-5p 37 
miR-10a-5p 338 
miR-519a-3p 86 
3. MicroRNAs in Breast Cancer 
3.1. MicroRNAs in Breast Cancer Tumor Tissue 
In breast cancer, several microRNAs are aberrantly expressed in tumor tissue compared to normal 
tissue. In a recent review, van Schooneveld lists some of the best described microRNAs in breast 
cancer including the oncogenic microRNAs miR-10b, -21, -155, -520c, -373, and the tumor suppressor 
microRNAs miR-31, -125b, -126, -200, -206, and -335 [52]. 
A well-known oncogenic microRNA is miR-21, which is overexpressed in breast cancer [53–55] 
and has been correlated with advanced stage, lymph node metastasis and poor prognosis [55]. 
Correspondingly, cell growth, migration and proliferation were inhibited when miR-21 was knocked 
down in MCF-7 and MDA-231 cells [56]. 
Among other well-studied microRNA clusters, the miR-17-92 cluster (comprising miR-17, miR-18a, 
miR-19a, miR-20a, miR-19b-1 and miR-92a-1) has been implicated in breast cancer by several studies. 
For example, in breast cancer cell lines, miR-17 has been shown to play an important role in promoting 
tumor cell migration and invasion [57]. In a study of ER+ breast cancer patients, ER has been  
shown to be a direct target of miR-18a and miR-18b [58], and miR-18a, together with miR-18b,  
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has been associated with features of basal-like breast cancer [59]. Moreover, miR-17, miR-18a and  
miR-20a showed enhanced expression in triple-negative tumors compared to luminal A tumors [60].  
In addition, miR-92a has been associated with tumor grade, cell migration and macrophage infiltration in 
breast cancer [61]. 
Studies report distinct functions of individual microRNAs, demonstrating that microRNAs have cell-, 
tissue- and organ-specific functions. As microRNAs appear to play important roles in breast cancer 
development, it seems likely that they have potential utility as prognostic and predictive biomarkers. 
3.2. Circulating MicroRNAs in Breast Cancer 
MicroRNAs have been detected in the circulation, either bound to lipids or proteins, inside 
apoptotic bodies from dead cells, or as part of circulating exosomes [62]. The presence of circulating 
microRNAs has also been shown in breast cancer patients. For instance, differential concentrations of 
miR-16, miR-107, miR-130a and miR-146a microRNAs were shown in plasma from 111 patients with 
different cancer subtypes [63]. In a cohort of 89 breast cancer patients (range 31–82 years), Roth et al. 
(2010) found elevated levels of circulating miR-10b, miR-155 and miR-34 in cell-free serum from 
breast cancer patients, compared with 29 healthy controls. The differences in relative concentrations of 
these microRNAs could be used to distinguish healthy controls from breast cancer patients, as well as 
metastatic (n = 30) from non-metastatic (n = 59) disease. Furthermore, in the 59 patients without 
distant metastases, higher levels of serum miR-34a correlated with advanced tumor stages [64].  
In 2012, Madhavan et al. demonstrated a significant correlation between higher levels of eight 
circulating microRNAs and circulating tumor cells (CTC), in metastatic breast cancer patients (n = 133) 
compared with healthy controls (n = 76), thus showing the potential of circulating microRNAs as 
surrogate markers for CTCs. In addition, they found that miR-200b was a promising prognostic marker 
of both overall- and progression-free survival (PFS) [65]. 
Compared to intracellular microRNA or microRNA in cell-free blood (plasma or serum), exosomes 
have proved to be an enriched and protective source of circulating microRNAs [66,67]. Tumor cells 
secrete exosomes, so-called tumor-derived exosomes [68], in higher amounts than normal cells. In fact, 
the cargo of the tumor-derived exosomes has been shown to reflect the cell and tissue it originates 
from. This opens up the possibility to use tumor-derived exosomes detected in blood to gain 
information on the remaining tumor cells, providing a minimally invasive biomarker to detect tumor 
cells, which might also reveal some of the oncogenic features of the tumor. 
The recent finding of microRNA in tumor-specific exosomes increases the potential for using 
microRNAs in blood as biomarkers for monitoring breast cancer characteristics and maybe even 
therapy response. Several studies have demonstrated the presence of tumor-derived exosomes 
containing microRNA, suggesting their potential as diagnostic, prognostic and predictive biomarkers. 
Furthermore, exosomes originating from drug resistant breast cancer cells have been shown to 
mediate drug efflux and resistance through so-called exosomal shuttle-microRNAs [69]. In a recent 
study of chemo-resistant breast cancer cells (resistant to Adriamycin and Docetaxel), exosomes were 
shown to mediate such chemo-resistance to cells that were still sensitive to these drugs. This transfer of 
resistance was likely due to intercellular transfer of specific exosomal microRNAs, potentially miR-100, 
miR-222 and miR-30a [70]. Moreover, in another recent study of tamoxifen-sensitive and  
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tamoxifen-resistant MCF-7 cells, exosomes released from resistant cells, were able to enter into 
tamoxifen-sensitive cells and release miR-221 and miR-222. These microRNAs then reduced the 
expression of p27 and ER in the recipient cells, thus decreasing their sensitivity to tamoxifen [71]. 
3.3. Tamoxifen-Related MicroRNAs Found in Breast Cancer Tissue 
In 2010, Cittelly et al. showed that miR-342-5p was differentially expressed in tamoxifen-sensitive 
versus tamoxifen-resistant cell lines. MicroRNA-342 expression was shown to be suppressed in the 
tamoxifen-resistant breast cancer cells, while a miR-342 inhibitor could promote resistance in the 
tamoxifen-sensitive cells. In addition, 16 tamoxifen-treated primary breast tumors (n = 6 with recurrence, 
n = 10 without recurrence) were analyzed by in situ hybridization (ISH) for miR-342 expression. Due 
to the low sample number estimates were imprecise, but the ISH results indicated that the level of 
miR-342 expression was about two-fold higher in tumors from the tamoxifen responders (i.e., those 
without recurrence or metastasis), compared to the non-responders. Furthermore, they performed a 
search for potential gene targets by microarray analysis of tamoxifen resistant breast cancer cell lines 
with restored level of miR-342 and control cells. This microanalysis showed that 13 genes were 
differentially expressed, of which GEMIN4 and BMP7 were validated as direct targets of miR-342.  
By using Ingenuity Pathway Analysis (IPA) for identification of functional pathways enriched with 
miR-342 regulated genes, they identified the Cell Death and Apoptosis of Breast Cancer Cells 
pathways as being the most significant. By canonical pathway analysis, IPA identified Mitotic Roles of 
Polo-Like Kinase as the pathway in which miR-342 genes were most significantly enriched [46]. 
In another study of 246 ER+ advanced breast cancers, higher expression of miR-30a-3p, miR-30c 
and miR-182 was associated with better response to tamoxifen treatment as measured by longer 
progression-free survival time; however, only miR-30c was shown to be an independent predictor. 
These patients were initially hormone-naïve, and received tamoxifen treatment following metastases or 
recurrence. For some of the samples included in this study both microRNA and mRNA expression data 
was available and used to analyze the potential underlying biological pathways associating these 
microRNAs with tamoxifen resistance. Accordingly, by using Global Test/Biocarta, miR-30c was 
found to be significantly correlated to HER2, signal transduction, and oncology pathway, whereas 
genes related to miR-30a-3p expression were significantly associated with Ceramide signaling 
pathway. Furthermore, both miR-30c and miR-30a-3p were negatively associated with the RAC1 cell 
motility signaling pathway. By searching publicly available databases, they also reported PPARGC1B, 
Makorin-3, UBAC1 and PTPDC1 as target genes for both miR-30c and miR-30a [49]. 
In 89 ER+ tamoxifen-treated breast cancers, a higher risk of recurrence and poorer clinical outcome 
was associated with a high level of miR-210 expression, compared with low miR-210 expression. 
Overexpression of miR-210 in ER+ MCF7 cells, and repression in ER− MDA-MB-231 cells induced 
the altered expression of several genes (data not shown). Gene set enrichment analysis of these 
differentially expressed genes showed their involvement in biological pathways involved such as cell 
cycle, cell adhesion and immune response [50]. 
Low levels of Enhancer of Zeste homolog 2 (EZH2), a target of miR-26a, have been associated with 
favorable outcome in tamoxifen-treated patients [72]. In a retrospective study by Jansen et al. of 235 
tamoxifen-treated patients with metastatic disease, high levels of miR-26a and decreased (EZH2) 
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expression was associated with clinical benefit and favorable time to progression. Furthermore, 
pathway analysis on microarray data from 65 of these tumors using the Global Test Approach (GTA) 
indicated the cell cycle regulatory pathway and the gene CDC2 to be correlated with miR-26a 
expression [51]. In cell line models CDC2 has been linked to tamoxifen response [73]. Patients with 
lower mRNA levels of CDC2 also showed a delay in disease progression compared to those with 
higher levels [51]. 
In a retrospective study, miR-126 and miR-10a were reported as being independent predictors for 
tumor relapse in a study restricted to post-menopausal women with breast cancer following tamoxifen 
treatment. By microarray profiling, they screened 12 patients (matched on age at diagnosis, tumor size, 
grade, nodal status, PgR-and Her2/neu-status, ER immune reactive (IR) score and radiotherapy) with 
(n = 6) and without (n = 6) relapse following five years of tamoxifen treatment for 1105 microRNAs. Of 
the 20 resulting microRNAs, miR-126 and mir-10a were confirmed by qRT-PCR in a set of 81 patients 
with and without relapse [47]. 
More recently, Ward et al. described that the microRNA cluster C19MC (comprising 50 microRNAs) 
is upregulated in tamoxifen-resistant versus tamoxifen-sensitive breast cancer cells; miR-519a was  
the microRNA most highly correlated with tamoxifen resistance. Oncogenic miR-519a was also 
demonstrated to increase resistance to tamoxifen-induced apoptosis as well as cell viability and cell 
cycle progression. In addition, the oncogenic properties of miR-519a were confirmed in gene 
expression datasets (Gene Expression Omnibus; GEO) of breast cancer patients. Among patients who 
received tamoxifen, higher expression of miR-519a was correlated with poorer disease-free survival in 
patients with ER+ tumors. Furthermore, by using algorithms for microRNA predictive targets, they 
validated the tumor suppressor genes PTEN of the PI3K/Akt pathway, and retinoblastoma protein 
(RB1) and CDKN1A/p21 as direct targets of miR-519a [48]. 
3.4. Candidate MicroRNAs in Signaling Pathways and Their Relevant Target Genes in  
Tamoxifen Resistance 
For each of the seven candidate microRNAs involved in patient tamoxifen response, our IPA 
analyses generated a list of predicted target genes (Table 2). 
Based on these results, IPA generated several networks depicting various direct and indirect targets 
for each of the selected microRNAs (Figures 4–6). The networks are graphically represented as 
explained in the legend in the figure. 
3.4.1. Targets of miR-26a  
The IPA-analyses demonstrate that six of the seven microRNAs are directly or indirectly associated 
with estrogen receptor; i.e. miR-126, miR-210, miR-26a, miR-519a, miR-30c and miR-342. As seen in 
Figure 4A, only miR-26a is highly predicted to directly target the ER gene (synonymous to ESR1 
shown in Figure 4), while the other microRNAs are only indirectly linked to ESR1. 
In the top network of miR-26a seen in Figure 6D, the well-known tumor suppressor protein 
retinoblastoma 1 (RB1) is predicted to be a direct target of miR-26a. As mentioned, Ward et al. 
identified RB1 to be targeted by miR-519a, but this is not mapped as a target in our IPA network for 
miR-519a. In 2007, deregulation of the RB1 pathway was shown to be associated with early recurrence 
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following tamoxifen monotherapy [74]. Also, cyclin-dependent kinase 6 (CDK6) is a direct target  
of miR-26a. 
As seen in Figure 4A, insulin-like growth factor 1 (IGF1) is also predicted as a direct target for 
miR-26a, this is very interesting as IGF1 is highly expressed in the presence of estradiol [75]. IGF1 
binds to the IGF1 receptor (IGF1R) and activates downstream pathways such as mitogen-activated 
protein kinase (MAPK) and PI3K pathways [76]. IGF1R and ER are strongly connected [77], and 
because of their crosstalk, the combination of IGF1R and ER antagonists has been clinically tested; 
although without convincing results [78]. 
3.4.2. Targets of miR-519 
In Figure 4B for miR-519a, Phosphoprotein membrane anchor with glycosphingolipid microdomains 1 
(PAG1) is seen as a direct target, while the proto-oncogene tyrosine-protein kinase Src is seen  
as an indirect target for miR-519a. Interestingly, by inhibiting the activity of Src in MCF7-cells,  
estrogen-stimulated proliferation was blocked [79]. Similarly, when constitutively active Src was 
expressed in endocrine-sensitive MCF-7 cells, the cells response to tamoxifen was attenuated, whereas 
tamoxifen-resistant MCF7-cells were re-sensitized when Src was suppressed. Additionally, elevated 
Src activity in tumor tissue was associated with clinically poor prognosis [80]. Furthermore, Src 
expression and Src-phosphorylation has been found to be increased in tamoxifen resistant T47D-cells. In 
the same study, membrane expression of Src on tamoxifen-treated breast tumor cells was associated 
with reduced disease-free and overall survival [81]. EGFR, MAPK and GPER1 are also indirect targets 
of miR-519a. GPER (G protein-coupled estrogen receptor) is inversely associated with tamoxifen 
resistance as confirmed in a cohort study of 103 patients [82]. Moreover, in a study by Yuan et al., 
GPER was shown to be important in the initiation/induction of tamoxifen resistance, and is thought to 
contribute to tamoxifen resistance by interaction with EGFR during long-term treatment with tamoxifen 
in breast cancer cells. This crosstalk leads to phosphorylation of MAPK and AKT thus stimulating  
ER-independent gene transcription and development of tamoxifen resistance [83]. 
3.4.3. Targets of miR-210 
Homeobox A1 (HOXA1) is predicted to act as a direct target for miR-210 (Figure 4C). The 
HOXA1 is an ER-regulated gene and the HOXA1 locus is believed to be involved in promoting 
growth of tamoxifen resistant breast cancer cells. ER forms a complex with lysine (K)-specific 
demethylase 3A (KDM3A), which indirectly regulates the transcriptional outcome of the HOXA1 
locus. This results in increased activation of ER in the presence of tamoxifen [84,85]. Heat shock 
protein 90 (Hsp90) is another direct target of miR-210. Chaperone molecules, of which Hsp90 is one 
of the most common, are involved in many important cellular pathways, especially in regulating the 
folding and sorting of proteins, as well as in the cells response to stress, cellular homeostasis, and cell 
cycle control [86]. It has been shown that tamoxifen and its metabolite 4-OHT may enhance the 
ATPase activity of Hsp90. The active metabolite was identified as a putative ligand for Hsp90 [87]. 
More recently, inhibition of Hsp90 has been shown to dramatically impair the emergence of resistance 
to hormone antagonists (tamoxifen and fulvestrant) in both cell culture and mice [88]. 
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Figure 4. Cont. 
Int. J. Mol. Sci. 2015, 16 24257 
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Figure 4. IPA networks for miR-26a, network 2 (A), miR-519a, network 1 (B) and miR-210, 
network 1 (C), centered on the estrogen receptor (ESR1). These networks created by IPA 
comprise networks with ER as a direct (miR-26a) or indirect (miR-519a and miR-210) 
target. Shaded boxes refer to direct targets whilst clear boxes refer to indirect targets of the 
specific miRNA. 
3.4.4. Targets of miR-30c 
In network 3 of miR-30c in Figure 5A, an estrogen receptor complex was found as an indirect target 
of miR-30c. In addition, forkhead box A1 (FOXA1) is a predicted target of miR-30c in this network, 
and is associated with ER. FOXA1 is important in ER-binding to chromatin, and is shown to be 
important for ER functioning as well as endocrine response in breast cancer cells [89,90]. 
miR-30c had the highest number of predicted target genes (1420), and as presented in Figure 6A,  
all were direct targets. Among them are cytochrome P450, family 24, subfamily A, polypeptide 1 
(CYP24A1), phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta (PIK3CD), 
phosphoinositide-3-kinase regulatory subunit 2 (PIK3R2) and TIMP metallopeptidase inhibitor 3 
(TIMP3). CYP24A1 is a member of the cytochrome P450 superfamily. This enzymatic family plays 
important roles in drug metabolism and the synthesis of steroids and cholesterol. CYP24A1 is involved 
in regulation of vitamin D3 level, calcium homeostasis and the vitamin D endocrine system [91].  
In both tamoxifen-sensitive and -resistant breast cancer cells, 1α,25-dihydroxyvitamin D3 has an 
antiproliferative effect [92]. TIMP3 inhibits matrix metalloproteinases, and is seen as a direct target of 
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miR-30c, but also a direct target for miR-221 and miR-222. Suppression of these microRNAs leads to 
an increased sensitivity to tamoxifen, mediated by TIMP3, in ER+ MCF-7 cells [93]. 
 
(A) 
 
(B) 
Figure 5. Cont. 
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(C) 
Figure 5. IPA networks for miR-30c, network (A), miR-126, network 1 (B) and miR-342, 
network 2 (C), centered on the estrogen receptor (ESR1). These networks created by IPA, 
comprise networks with ER as an indirect target (miR-126 and miR-342), whereas miR-30c 
has an ER-complex as an indirect target. Shaded boxes refer to direct targets whilst clear 
boxes refer to indirect targets of the specific miRNA. 
In addition, PIK3CD and PIK3R2 are also two direct targets of miR-30c. PIK3R2 is also seen as a 
direct target of miR-126 (see Figure 5A). Another such kinase, the phosphatidylinositol-4,5-bisphosphate 
3-kinase (PIK3CA), is a predicted direct target gene of miR-10a. PIK3CD, PIK3R2 and PIK3CA are 
all members of the Class I phosphoinositide 3-kinase (PI3K) enzymes, which have been shown to be 
involved in several types of cancer and involved in the Akt/mTOR pathway [94,95]. PI3KCA 
mutations are frequent in breast cancer, especially in ER+ breast cancer. In fact, 40% of luminal breast 
cancers have PI3KCA mutations [96], making this the most common mutation in breast cancer. 
Furthermore, the overall mutation rate in the whole PI3K pathway in breast cancer is >70% [97]. 
Activation of the PI3K pathway can lead to activation of proliferation, or growth and inhibition of 
apoptosis. Even though PIK3CA mutations have a high mutation frequency in breast cancer patients,  
it does not seem to be a good independent predictor in the context of endocrine therapy [98]. 
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3.4.5. Targets of miR-126 
As seen in Table 2, miR-126 had the fewest predicted targets genes (37) in our IPA analysis.  
In network 1 of miR-126 (Figure 5B), PI3KR2 is shown as a direct target, whereas Hsp 70, CLTC and 
TP53 are shown as indirect targets. Hsp70 is a component of the molecular chaperone machinery, 
which aids in assembly and trafficking of steroid receptors. Clathrin heavy chain (CLTC) is involved 
in intracellular trafficking as well as endocytosis, and was recently identified as a target of miR-574-3p, 
which again was shown to modulate tamoxifen-resistance in MCF-7 cells [99]. 
3.4.6. Targets of miR-342 
As seen in Figure 6C, the transcription factor Zinc Finger E-box Binding Homeobox (ZEB1) is a 
direct target of miR-342. ZEB1 has previously been associated with increased tamoxifen resistance 
and reduced expression of miR-200 in LY2 endocrine resistant breast cancer cells [100]. As illustrated 
in the network, another direct target of miR-342 is B-cell CLL/Lymphoma 2 (BCL2), an oncogene that 
is involved in regulation of apoptosis. In tamoxifen resistant cell line studies miR-15a and miR-16 have 
also been shown to activate BCL2 expression, and thereby promote resistance in HER2/ER+ breast 
cancer cells [101]. In Figure 5C both ESR1 and PGR are shown as indirect targets of miR-342. 
Homeobox B1 (HOXB1) is seen as a direct target. 
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Figure 6. Cont. 
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(D) 
Figure 6. Top networks of miR-30c, network 1 (A), miR-10a, network 1 (B), miR-342, 
network 1 (C) and miR-26a, network 1 (D). Shown here are networks with the highest 
scores calculated by IPA, showing direct targets of the miRNAs. Shaded boxes refer to 
direct targets whilst clear boxes refer to indirect targets of the specific miRNA. 
3.4.7. Targets of miR-10a 
As seen in Figure 6A, apart from PIK3CA, miR-10a also targets heat-shock protein 90 (Hsp90) and 
Histone H3. Hsp90 is discussed previously, see Figure 4C. Histone H3 is part of the nucleosome and 
involved in transcription regulation and proliferation. Interestingly, miR-10a and miR-342 share five 
targets in their top rated networks; CBX5, FOSL2, Histone H3, RNA polymerase II and spectrin, 
alpha, erythrocytic 1 (SPTA1). Chromobox homolog 5 (CBX5) is a heterochromatin protein associated 
with centromeres. Spectrin alpha 1 (SPTA1) is a scaffold protein. FOS-Like antigen 2 (FOSL2) is a 
member of the Fos gene family that encodes leucine zipper proteins and have been implicated in cell 
proliferation, transformation and differentiation [91]. However, no correlations between these genes 
and tamoxifen resistance have been reported at this moment. 
4. Discussion 
In the present paper, we review the potential of miRNAs as biomarkers for predicting the response 
to tamoxifen in breast cancer patients (Figure 7). Surprisingly, among more than 2400 known 
microRNAs, only seven have been associated with tamoxifen resistance according to our literature 
search, where we focused only on studies that included patient material. These seven microRNAs 
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could well be part of the bigger picture, as many more microRNAs have been correlated with tamoxifen 
resistance from in vitro analyses. 
Our IPA analysis suggests that signaling involved in endocrine resistance can be divided in two 
main signaling networks: One related to ER-signaling (Figure 4) and the second to membrane-related 
receptors (i.e., EGFR, HER-2, IGF) (Figure 5). As observed in these predicted target networks and 
discussed before, tamoxifen resistance does not seem to be directly related to changes in ER itself, and, 
as Figure 5 implies, changes in various molecules in the network surrounding ER could contribute to 
tamoxifen resistance. These networks and pathways may have an important role in tamoxifen 
resistance, and therefore the role of these microRNAs should be further investigated. Notably, no link 
between microRNAs and tamoxifen metabolic pathways (e.g., CYP2D6) was found in our IPA 
analysis. This may reflect the negative results in studies examining the relation between genetic 
polymorphisms and relapses on tamoxifen treatment [102]. 
As an alternative explanation of endocrine resistance, the switch to other ER signaling independent 
pathways (e.g., the EGFR pathway) that drive the cellular survival processes are reported [36,103]. 
The IPA analyses also suggest that microRNAs related to signal networks independent of ER signaling 
might have a direct and strong connection to these pathways, indicating that these mechanisms are 
more important predictors of endocrine resistance than ER-related signaling networks. 
The underlying heterogeneity of breast tumors is one important explanation of this observation [104].  
In ER+ tumors (i.e., ≥1% positively stained tumor cells by immunohistochemistry) most clones may 
respond to endocrine treatment, while others are non-responders. In the former type, up-regulation of 
various receptor tyrosine kinases (RTKs), i.e., HER-2 may take place [105,106]. This phenomenon is 
thought to be an escape mechanism from endocrine control of cancer cells. 
Examples of microRNAs involved in the switch to alternative ER-independent pathways are miR-10a, 
miR-126 and miR-30c relation to PI3K signaling. This pathway is a central node in mediating growth 
factor receptor signaling, and is known to characterize the more aggressive and less endocrine sensitive 
luminal B-subtype of breast cancers [107]. Studies indicate that only a slight loss in inhibition of this 
potent signaling pathway (i.e., loss of PTEN) is enough to induce endocrine resistance. Interestingly, 
this escape from endocrine control can be restored by targeting mTOR, Protein Kinase B (Akt) or 
Mitogen Activated Kinase that are located downstream in the same pathway [108]. Moreover, lessons 
from the treatment of metastatic ER+ breast cancer patients support the importance of targeting RTKs 
to restore the endocrine sensitivity in breast cancer tissue. Reliable predictive markers for the 
PI3K/Akt/mTOR axis are necessary to indicate the need for co-targeting PI3K and ER pathways to 
restore endocrine sensibility. The importance of these microRNAs is demonstrated since they may help 
identify the timing of change in treatment strategy. 
Interestingly, microRNAs are involved in various hallmarks of cancer and can interact with several 
characteristics at the same time [109]. From our list of microRNAs involved in tamoxifen resistance 
(Table 2), cell proliferation and invasion is enhanced by elevation of miR-210 [50,110], cell survival is 
promoted by a decrease in miR-26a [111], and angiogenesis is stimulated by elevation of miR-126 [112]. 
Multigene assays show that proliferation related genes dominate the basis of the predictive effect of 
chemotherapy in endocrine responsive early breast cancer [113,114]. However, molecular subtyping is 
suitable for short-term evaluation only (i.e., the first five years of follow, as they seem to lose their 
power in long-term perspectives [115]). 
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Figure 7. Overview of the possible involvement of candidate microRNAs in tamoxifen 
resistance pathways, based on the present literature search and IPA analysis. MicroRNAs 
miR-10a, -26a, -30c, -126, -210, -342-5p and -519a and their direct (pink lines) or indirect 
(dotted lines) targets. BCL2: B-cell CLL/lymphoma 2; CDK6: cyclin-dependent kinase 6; 
CYP24A1: cytochrome P450, family 24, subfamily A, polypeptide 1; IGF1: insulin-like 
growth factor 1; FOXA1: forkhead box A1; HOXA1: homeobox A1; HOXB1: homeobox B1; 
Hsp90: heat-shock protein 90. KDM3A: lysine (K)-specific demethylase 3A. PAG1: 
phosphoprotein membrane anchor with glycosphingolipid microdomains 1; PI3K: 
phosphoinositide 3-kinase; PIK3CA: phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic 
subunit alpha; PIK3CD: phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit 
delta; PIK3R2: phosphoinositide-3-kinase, regulatory subunit 2 (beta); RB1: retinoblastoma 1; 
TIMP3: TIMP metallopeptidase inhibitor 3; ZEB1: zinc finger E-box binding homeobox 1. 
Black arrow: normal pathway. Blue arrow: tamoxifen pathway. Crossed arrow: disrupted 
pathway. Pink inhibition arrow: direct inhibition by miRNA. Dotted pink inhibition arrow: 
indirect inhibition by miRNA. 
Thus, since microRNAs interact with several hallmarks of cancer simultaneously, detailed 
characterization of these microRNAs may provide an improved understanding of the underlying 
resistance mechanism as compared to the currently established biomarkers in breast cancer. Promising 
predictors for late recurrences are involvement of micro-environmental stromal factors and the EMT 
processes [116]. Factors that can predict long-term cancer cell survival will be of particular interest 
since endocrine therapy is given over a long time span (Figure 2). 
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Clinicians face various challenges when deciding the most effective endocrine therapy for each 
patient. The following four clinical scenarios all have the need for reliable biomarkers that can point 
out which patients can be assigned tamoxifen treatment from those who cannot. First, in younger 
patients, tamoxifen is increasingly given as adjuvant therapy to patients operated for ductal carcinoma  
in situ. It increases event-free survival, even at the population level [117]; Second, in the younger  
pre-menopausal patients with invasive ER+ breast cancer, it is recommended to administer either  
10 years with tamoxifen, or five years with OFS in addition to tamoxifen or AI (Figure 2). The latter 
regime is shown to be superior to tamoxifen monotherapy, but is not very well tolerated [118]; Third, 
in postmenopausal women AIs for five years upfront or for at least two years followed by tamoxifen 
for three years is recommended (Figure 2); Fourth, the elderly co-morbid patients are often treated 
with endocrine treatment only, while tumor size is under surveillance. Elderly women are especially 
vulnerable to AIs, e.g., due to high fracture rates [119]. Since the side effects of AIs are quite substantial 
and probably highly underestimated [120], biomarkers that can identify tamoxifen-responsive tumors, 
so that AIs can be avoided, are clinically relevant. Selection of the tamoxifen-sensitive tumors by 
means of reliable biomarkers would be clinically very helpful in managing these patients, also to indicate 
development of endocrine resistance so other treatment options can be considered (i.e., radiation 
therapy or surgery). All these scenarios share the need to distinguish between tamoxifen and alternative 
regimens that comprise either OFS or an AI. Today, clinicians are not able to take into account the 
heterogeneity of the tumors; as a consequence, we treat breast cancer with a wide specter of ER 
positivity (i.e., ranging from ≥1% up to 100%) with the same endocrine strategy. 
The tumor heterogeneity calls for a double strategy to monitor endocrine effectiveness. During the 
early phase of the tamoxifen treatment, identification of possible endocrine sensitive/responsive 
tumors might provide important information whether or not endocrine therapy will work. Later, during 
long-term follow-up, markers that can identify emerging endocrine resistant clones at an early  
stage might allow change of therapy before the endocrine resistance becomes clinically evident. This  
“dual-approach” is more in line with the intrinsic tumor biology of breast cancer. In the large adjuvant 
ATAC [34] and BIG-1 98 trials [35], tamoxifen was compared with anastrozole and letrozole, 
respectively. These studies provide valuable long-term follow-up data on relapse and survival in four 
different treatment arms. In order to get an indication of which microRNA might depict endocrine 
sensitivity in the adjuvant setting, microRNA profiling of patients from these two studies could 
promptly provide valuable information on this issue. Such studies would also provide microRNA 
profiles from treatment arms that switch from tamoxifen to AI and vice versa. Moreover, microRNA 
analyses in population-based epidemiological studies (e.g., our ongoing work) will strengthen the 
findings from clinical trials. Candidate microRNAs identified should be validated in other prospective 
trials. Such prospective studies should comprise a combinatory analysis of microRNA expression 
profiles in the primary tumor together with concurrent free microRNAs in serum or plasma. Moreover, 
patients enrolled in neo-adjuvant treatment trials and endocrine-controlled comorbid elderly patients, 
are especially suitable for repeated tumor biopsies during treatment. Repeated microRNA profiling  
of both primary tumors and plasma microRNAs during treatment will elucidate which microRNAs 
might be promising marker candidates; both for endocrine sensitivity (if the tumor shrinks) as well as 
endocrine resistance (if the tumor stops responding or increases in size). 
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5. Conclusions 
In conclusion, endocrine treatment remains one of the most important strategies for eradicating 
and/or controlling ER positive breast cancer. Biomarkers of endocrine responsiveness and resistance 
are urgently needed to help clinicians in making treatment decisions. As microRNAs are able to exert 
control at the translational level, they are an important link between coding genes and the various 
cellular processes. Hence, microRNAs are certainly promising candidate biomarkers that could be used 
in the clinic to guide tamoxifen treatment. One immediate aim must be to include a combined microRNA 
profiling in tumor tissues and in plasma in on-going and future clinical studies with long-term follow-up. 
This approach seems like a small step for the role of microRNA as a biomarker, but will undoubtedly 
bring the clinical knowledge of microRNA in endocrine treatment in breast cancer a giant leap forward. 
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